Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
出版年份 2011 全文链接
标题
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
作者
关键词
-
出版物
Targeted Oncology
Volume 6, Issue 1, Pages 5-16
出版商
Springer Nature
发表日期
2011-04-12
DOI
10.1007/s11523-011-0172-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- mTOR inhibition in advanced renal cell carcinoma
- (2010) Christoph Eimer et al. ANTI-CANCER DRUGS
- Targeting mTOR in renal cell carcinoma
- (2010) Gary R. Hudes CANCER
- Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer
- (2010) Wenfeng Yang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma
- (2010) C. Lance Cowey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Repeatability of Metabolically Active Volume Measurements with 18F-FDG and 18F-FLT PET in Non-Small Cell Lung Cancer
- (2010) V. Frings et al. JOURNAL OF NUCLEAR MEDICINE
- Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma
- (2010) Nicholas J. Hellenthal et al. JOURNAL OF UROLOGY
- FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
- (2009) D Cejka et al. BRITISH JOURNAL OF CANCER
- Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α
- (2009) Robert A. Figlin et al. CANCER
- [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
- (2009) Wen Wee Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non-Small Cell Lung Cancer with the mTOR Inhibitor Everolimus
- (2009) L. Nogova et al. JOURNAL OF NUCLEAR MEDICINE
- The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer
- (2008) Sumanta Kumar Pal et al. Clinical Lung Cancer
- Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma
- (2008) Anil A. Thomas et al. JOURNAL OF UROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started